Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation
0301 basic medicine
Binding Sites
Ubiquitination
Nuclear Proteins
Protein Tyrosine Phosphatase, Non-Receptor Type 11
Polymorphism, Single Nucleotide
3. Good health
Gene Expression Regulation, Neoplastic
Pancreatic Neoplasms
MicroRNAs
03 medical and health sciences
DNA Repair Enzymes
STAT1 Transcription Factor
Case-Control Studies
Proteolysis
Humans
RNA, Long Noncoding
RNA Splicing Factors
Extracellular Signal-Regulated MAP Kinases
Pancreas
Cell Proliferation
Genome-Wide Association Study
Signal Transduction
DOI:
10.1038/ng.3568
Publication Date:
2016-05-24T13:21:18Z
AUTHORS (25)
ABSTRACT
Genome-wide association studies have identified several loci associated with pancreatic cancer risk; however, the mechanisms by which genetic factors influence the development of sporadic pancreatic cancer remain largely unknown. Here, by using genome-wide association analysis and functional characterization, we identify a long intergenic noncoding RNA (lincRNA), LINC00673, as a potential tumor suppressor whose germline variation is associated with pancreatic cancer risk. LINC00673 is able to reinforce the interaction of PTPN11 with PRPF19, an E3 ubiquitin ligase, and promote PTPN11 degradation through ubiquitination, which causes diminished SRC-ERK oncogenic signaling and enhanced activation of the STAT1-dependent antitumor response. A G>A change at rs11655237 in exon 4 of LINC00673 creates a target site for miR-1231 binding, which diminishes the effect of LINC00673 in an allele-specific manner and thus confers susceptibility to tumorigenesis. These findings shed new light on the important role of LINC00673 in maintaining cell homeostasis and how its germline variation might confer susceptibility to pancreatic cancer.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (65)
CITATIONS (224)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....